CytoDyn (CYDY) EBITDA (2010 - 2026)

CytoDyn (CYDY) has 17 years of EBITDA data on file, last reported at -$6.3 million in Q1 2026.

• Quarterly EBITDA fell 57.46% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$38.0 million (down 569.57% YoY) and the FY2025 annual result came in at $9.7 million, up 153.5% from the prior year.
• EBITDA rose to -$6.3 million in Q1 2026, from -$21.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $22.4 million in Q3 2024 to a low of -$79.0 million in Q2 2022.
• A 5-year average of -$10.6 million and a median of -$4.9 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA surged 586.49% — and 2025, when it tumbled 485.06%.
• Tracing CYDY's EBITDA over 5 years: stood at -$23.2 million in 2022, then jumped by 85.33% to -$3.4 million in 2023, then decreased by 9.09% to -$3.7 million in 2024, then plunged by 485.06% to -$21.7 million in 2025, then surged by 70.94% to -$6.3 million in 2026.
• The last three EBITDA figures came in at -$6.3 million (Q1 2026), -$21.7 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.